Elutia Inc. Stock

Equities

ELUT

US05479K1060

Pharmaceuticals

Delayed Nasdaq 04:30:00 2024-04-24 pm EDT 5-day change 1st Jan Change
2.89 USD +0.84% Intraday chart for Elutia Inc. -4.93% +33.80%
Sales 2024 * 26.45M Sales 2025 * 39M Capitalization 70.37M
Net income 2024 * -34M Net income 2025 * -28M EV / Sales 2024 * 2.66 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.8 x
P/E ratio 2024 *
-1.8 x
P/E ratio 2025 *
-2.23 x
Employees 54
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.13%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.84%
1 week-4.93%
Current month-8.25%
1 month-12.16%
3 months-28.99%
6 months+147.01%
Current year+33.80%
More quotes
1 week
2.81
Extreme 2.8095
3.03
1 month
2.75
Extreme 2.7501
3.36
Current year
2.16
Extreme 2.16
4.19
1 year
1.10
Extreme 1.1001
4.19
3 years
1.10
Extreme 1.1
12.92
5 years
1.10
Extreme 1.1
18.20
10 years
1.10
Extreme 1.1
18.20
More quotes
Managers TitleAgeSince
Founder 52 15-08-05
Founder 63 15-08-05
Director of Finance/CFO 56 20-09-27
Members of the board TitleAgeSince
Founder 63 15-08-05
Director/Board Member 68 20-08-31
Founder 52 15-08-05
More insiders
Date Price Change Volume
24-04-24 2.89 +0.84% 6,674
24-04-23 2.866 -1.85% 4,416
24-04-22 2.92 +0.34% 4,147
24-04-19 2.91 -4.59% 3,368
24-04-18 3.05 +0.33% 3,260

Delayed Quote Nasdaq, April 24, 2024 at 04:30 pm EDT

More quotes
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Women’s Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Women’s Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.89 USD
Average target price
5.5 USD
Spread / Average Target
+90.31%
Consensus